Literature DB >> 7222192

High performance liquid chromatographic assay of dexamethasone in plasma and tissue.

B E Cham, B Sadowski, J M O'Hagan, C N de Wytt, F Bochner, M J Eadie.   

Abstract

Dexamethasone in plasma and in tissue is specifically quantitated by high performance liquid chromatography (ultraviolet detection at 254 nm) with an octadecyl silane reversed-phase chromatographic column employing peak-height ratio determination (internal standard, cyheptamide). The sample is first washed with heptane under alkaline conditions. The dexamethasone is then extracted from the washed sample with dichloromethane containing the internal standard. Dichloromethane is evaporated to dryness, and the concentrated extract is dissolved in tetrahydrofuran and then injected into a high performance liquid chromatograph. Dexamethasone and internal standard are eluted with a mixture of acetic acid, methanol, butanol, and water (11/19/30/440 by volume). Sensitivity limit is 10 ng, with linear response to at least 1.000 mg/liter plasma. Analytical recovery of dexamethasone from plasma is almost complete, and approximately 87% dexamethasone is recovered from brain tissue. Intra-assay precision (CV) is 1.07% (N = 11), and interassay precision is 1.38% (N = 5). No interference occurred in plasmas from patients treated with various drugs other than dexamethasone. Dexamethasone was estimated in plasma and in tumor tissue from patients on dexamethasone therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7222192

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients.

Authors:  T R Brophy; J McCafferty; J H Tyrer; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Intraoperative pharmacokinetics of dexamethasone.

Authors:  J McCafferty; T R Brophy; J D Yelland; B E Cham; F Bochner; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

3.  Cortisol production during high dose dexamethasone therapy in neurological and neurosurgical patients.

Authors:  T Brophy; J B Chalk; K Ridgeway; J H Tyrer; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

4.  Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.

Authors:  J B Chalk; K Ridgeway; T Brophy; J D Yelland; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

5.  Dexamethasone and radiation response in the Lewis lung tumour model.

Authors:  O O Agboola; J A Raleigh; J E Pedersen; R C Urtasun; G Barron
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.